Movement Disorders

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Stewart Factor, DO.

The chief scientific officer of the Parkinson’s Foundation also talked about the recent PD Health @ Home series created by the foundation.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 5, 2021.

Genetically-index TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease and ulcerative colitis, and increased multiple sclerosis risk.

Additionally, the therapy’s developer Yumanity Therapeutics announced the results of a single ascending dose study and enrollment in a multiple ascending dose study.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 26, 2021.

Tavapadon’s rare combination of efficacy and minimal adverse effects may indicate a step forward in the treatment of Parkinson disease.

Here's what is coming soon to NeurologyLive.

Bijan Nejadnik, MD, chief medical officer, SanBio, also thanked neurological experts that collaborated on the phase 2 STEMTRA trial.

The chief scientific officer of the Parkinson’s Foundation discussed the importance of screening for mood disturbances in patients with PD.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 19, 2021.

Masahito Kawabori, MD, PhD, associate professor, Hokkaido University, discussed results of the phase 2 STEMTRA trial.

Researchers found that 93% of patients with AS exhibited dystonia in their limbs, mouth, neck, or trunk.

Here's what is coming soon to NeurologyLive.

ACI-12589 aims to become the world’s first diagnostic tool for assessing brain alpha-synuclein pathology in patients with Parkinson disease.

The chief scientific officer of the Parkinson’s Foundation discussed the state of mental health services for people with Parkinson disease during the COVID-19 pandemic.

AMT-130 is uniQure’s first clinical program focusing on the central nervous system incorporating its proprietary miQURE silencing technology platform.

Neurology News Network for the week ending February 13, 2021.

Both therapeutic programs utilize AAD2-GDNF gene therapy targeted to brain structures vulnerable to Parkinson disease and multiple system atrophy.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 12, 2021.

The treatment can be used in children who do not respond well to anticholinergic medications.

Data from a small study showed patients experienced significant improvements in MDS-UPDRS III scores after 4 months of treatment with single-hemisphere FUS.

Here's what is coming soon to NeurologyLive.